Revenue GrowthSustained revenue growth near ~17% indicates durable end-market demand and product traction. Over a 2–6 month horizon this supports predictable top‑line expansion, enables better capacity planning and reinvestment, and provides a base for scale economies that can improve future profitability.

Profit MarginsHealthy EBIT and net margins >17% reflect structural cost efficiencies and pricing power in the business model. These margins provide an earnings buffer against input shocks, support internal funding of R&D or expansion, and enable sustained profit generation if margins are maintained.

Balance Sheet StrengthExtremely low leverage and a high equity ratio give the company financial flexibility and resilience. This structural conservatism lowers bankruptcy risk, preserves capacity for opportunistic M&A or capex, and supports creditworthiness and long-term strategic investments without heavy interest burden.

Bears Say

Cash ConversionPersistent negative free cash flow and an OCF-to-net-income ratio of 0.20 show earnings are not being converted into cash efficiently. Over months this can constrain funding for growth, force external financing, and limit the company’s ability to sustain capex or return capital despite reported profits.

Gross Margin PressureA declining gross margin signals rising production costs or weakening pricing power. If this trend persists it will erode operating margins and free cash flows, reduce the firm’s ability to absorb cost shocks, and necessitate structural adjustments in pricing, sourcing, or product mix to restore profitability.

EPS VolatilityA large negative EPS growth rate (~-54%) indicates earnings volatility or one-off impacts materially hurt profitability. Sustained EPS weakness undermines reinvestment capacity and investor confidence, and if recurring may limit the company’s ability to fund strategic initiatives or maintain dividend/return policies.

Alpa Laboratories Limited News

Alpa Laboratories to Shut Trading Window Ahead of Q3 FY2026 Results

An update from Alpa Laboratories Limited ( ($IN:ALPA) ) is now available. Alpa Laboratories Limited has announced that...

2M ago

ALPA

Alpa Laboratories Announces Q3 2025 Financial Results

Alpa Laboratories Limited ( ($IN:ALPA) ) has shared an update. Alpa Laboratories Limited has announced the approval of...

3M ago

ALPA

ALPA FAQ

What was Alpa Laboratories Limited’s price range in the past 12 months?

Alpa Laboratories Limited lowest stock price was ₹61.18 and its highest was ₹124.88 in the past 12 months.

What is Alpa Laboratories Limited’s market cap?

Alpa Laboratories Limited’s market cap is ₹1.48B.

When is Alpa Laboratories Limited’s upcoming earnings report date?

Alpa Laboratories Limited’s upcoming earnings report date is Jun 02, 2026 which is in 99 days.

How were Alpa Laboratories Limited’s earnings last quarter?

Alpa Laboratories Limited released its earnings results on Feb 11, 2026. The company reported ₹0.904 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.904.

Is Alpa Laboratories Limited overvalued?

According to Wall Street analysts Alpa Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alpa Laboratories Limited pay dividends?

Alpa Laboratories Limited does not currently pay dividends.

What is Alpa Laboratories Limited’s EPS estimate?

Alpa Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Alpa Laboratories Limited have?

Alpa Laboratories Limited has 21,040,600 shares outstanding.

What happened to Alpa Laboratories Limited’s price movement after its last earnings report?

Alpa Laboratories Limited reported an EPS of ₹0.904 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.091%.

Which hedge fund is a major shareholder of Alpa Laboratories Limited?

Currently, no hedge funds are holding shares in IN:ALPA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Alpa Laboratories Limited

Alpa Laboratories Limited engages in manufacturing, marketing, and selling pharmaceutical finished dosage forms in India. It offers ethical, generic, and over the counter products in various finished dosage forms, including injections, tablets, capsules, eye and ear drops, ointments, creams, and gels for human use; and boluses, injections, and intra-mammary infusions for veterinary use. The company also provides drugs in various categories, such as anti-infectives comprising antibacterial, antibiotics, antifungals, antiprotozoals, and antivirals; analgesics; anti-inflammatory drugs; cough and cold drugs; cardiovascular drugs; anti-diabetics; nutritional supplements; psychotropic drugs; and skin care preparations, as well as ear and eye care preparations. It sells its products through distributors, retail chemists, retail pharmacy stores, and hospitals. The company also exports its products to South and Central America, Africa, and Asia, and CIS countries. Alpa Laboratories Limited was founded in 1967 and is based in Indore, India.